APM: Aptorum Group Limited Net earnings per share (EPS TTM)
Revenue volatility from staphylococcus therapy and age-related pathologies is evident through the rolling year earnings per share metric featured on the GURU.Markets analytical chart for Aptorum Group Limited (APM). The value -0.35 indicates the level of this metric. An academic image in oncology and the overcoming of sanction barriers blocking international biomaterial logistics and clinical tests help smooth the trend.
Comprehensive metric breakdowns and analytics for Aptorum Group Ltd (APM)
- stock price and consensus target price:
- market capitalization information:
- business book valuation details:
- debt and liquidity details:
Debt to Equity Aptorum Group Limited|APM - Long-Term Liabilities to Equity|Short-Term Debt to Equity Ratio Aptorum|APM - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio Aptorum Group Limited|APM - Long-Term Debt|Company Short-Term Debt Aptorum Group|Quick Liquidity Indicator aptorumgroup.com
- earnings and multiples data:
APM - Net Profit|Expected Profit Aptorum Group Limited|APM - Price to Earnings Ratio|Projected Price to Earnings Aptorum|APM - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Aptorum Group Limited|APM - Operating profit before depreciation charges|Earnings per share for the last twelve months Aptorum Group|APM - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months aptorumgroup.com|APM - Earnings per share growth rate in current year|Expected earnings per share growth for next year Aptorum Group Limited
Summary company analytics:APM - aptorumgroup.com
The scaling of innovative drugs by Aptorum Group Limited (APM) is reflected in the trend of the annual EPS TTM. This metric represents the net profit allocated per ordinary share over the last twelve months. The calculation allows for an assessment of real capital generation efficiency, taking into account the equity structure. For the pharmaceutical business, this indicator serves as a marker of financial stability during costly clinical trials. The steady growth of the line confirms the success of long-term expansion into the therapeutic platforms market.
Main competitors
Haleon plc - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KVUE (kenvue.com)|VRNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Jyong Biotech Limited (MENS)|Earnings per share for the last twelve months Ligand Pharma|AMRX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PRGO|Net earnings per share (EPS TTM) alvotech.com (ALVO)|Earnings per share for the last twelve months Liquidia LQDA|GLPG (Galapagos N.V.) - Earnings per one share for the last 12 months|ANIP: Net earnings per share for the last 12 months|Afrezza - Earnings per share for the last four quarters|Amphastar Pharmaceuticals (AMPH) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months pacira.com (PCRX)|Earnings per share for the last twelve months ARS Pharmaceuticals, Inc.|TBPH: Earnings per share for the trailing year|Net earnings per share for the last 12 months AQST (Aquestive Pharma)|Net earnings per share (EPS TTM) scpharmaceuticals.com (SCPH)|Earnings per share for the last twelve months Tectonic Therapeutic TECX|TNXP - Net earnings per share for the last 12 months|SXTC: Net earnings per share for the last 12 months|Earnings per share for the trailing year EPRX (Eupraxia Pharmaceuticals)|BHST: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Invizyne EXOZ|Earnings per share for the last twelve months Oramed|ENTX: Earnings per share for the trailing year|Earnings per share for the last twelve months MindWalk Holdings Inc. (HYFT)|ABVC - Net earnings per one share for the last twelve months|Cumberland Pharma - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Quantum BioPharma Corp QNTM|FGEN - Earnings per share for the last twelve months|Earnings per one share for the last 12 months TELO|RANI (ranitherapeutics.com) - Net earnings per share for the last 12 months|Synergy CHC - Earnings per share for the trailing year|Earnings per share for the last twelve months Rallybio Corp|Earnings per share for the last twelve months LEXX|Net earnings per share (EPS TTM) PULM|Net earnings per share for the last four quarters ftzy.com.cn|Earnings per share for the last twelve months Lyra Therapeutics LYRA|IBO - Net earnings per share for the last 12 months|TNF Pharma - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters cbdMD, Inc. YCBD|PRFX (PainReform Ltd.) - Net earnings per share for the last 12 months|CYTO: Earnings per share for the last four quarters|LIPO (Lipella Pharmaceuticals, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months OptiNose Inc OPTN|Net earnings per share (EPS TTM) PIRS|Procaps Group Corp - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) PTPI (Petros Pharmaceuticals)|Net earnings per share (EPS TTM) qlsyy.net QLI|SLRN - Earnings per share for the last twelve months|Earnings per one share for the last 12 months TFFP
